<DOC>
	<DOCNO>NCT02889003</DOCNO>
	<brief_summary>Single-center study , prospective , phase II trial . The study objective : - To assess safety combination Pioglitazone TKI CML subject experience loss MMR follow first TKI discontinuation . - To assess survival without loss MMR 12 month period follow second TKI discontinuation subject achieve maintain &lt; MR4.5 combination Pioglitazone TKI administer least 6 month .</brief_summary>
	<brief_title>Second STOP After Pioglitazone Priming CML Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . CML phase . patient MMR 2 . Loss MMR follow first TKI discontinuation trial . 3 . Patient prior treat imatinib , dasatinib , nilotinib , bosutinib 4 . Age &gt; 18 year . 5 . Serum bilirubin &lt; 1.5 x upper limit normal value . 6 . AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5x upper limit normal value . 7 . Females child bear potential must agree abstain sexual activity use medically approve contraceptive measure/regimen 3 month treatment period . Women child bear potential must negative urine pregnancy test time enrollment . Acceptable method birth control include oral contraceptive , intrauterine device , transdermal/implanted injected contraceptive abstinence . 8 . Males must agree abstain sexual activity agree utilize medicallyapproved contraception method 3 month treatment period . 9 . Signed informed consent . 10 . Be able willing comply study visit procedure . 1 . Known loss CCyR marrow cytogenetic blood FISH BCRABL1 . 2 . Loss CHR . 3 . Participation another clinical trial investigative drug within 30 day prior study enrolment . 4 . Prior allogeneic hematopoietic stem cell transplantation . 5 . Patient require antidiabetic medication manage hyperglycemia . 6 . Cardiovascular disease : history congestive heart failure , myocardial infarction within 6 month study entry , symptomatic cardiac arrhythmia require treatment . 7 . History bladder cancer . 8 . Diagnosed hematuria . 9 . Known history osteoporosis . 10 . Known history macular edema . 11 . Known history ABL1domain mutation predict resistance discontinue TKI . 12 . Known allergy PIO . 13 . Pregnant breastfeeding . 14 . Use TZD within 28 day prior enrollment . 15 . Significant gastrointestinal condition could potentially impair absorption disposition drug . 16 . Uncontrolled peripheral edema ( 2+ ) etiology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>